Helicobacter pylori treatment in Turkey: Current status and rational treatment options

Creative Commons License

Kaplan M., Tanoglu A., Duzenli T., TÖZÜN A. N.

NORTHERN CLINICS OF ISTANBUL, cilt.7, sa.1, ss.87-94, 2020 (Hakemli Dergi) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 7 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.14744/nci.2019.62558
  • Dergi Adı: NORTHERN CLINICS OF ISTANBUL
  • Sayfa Sayıları: ss.87-94
  • Anahtar Kelimeler: Eradication, Helicobacter pylori, proton pump inhibitors, Turkey, TRIPLE THERAPY, ERADICATION REGIMENS, LEVOFLOXACIN, PREVALENCE, INFECTION, RATES, ESOMEPRAZOLE, METAANALYSIS, CONSENSUS, BISMUTH
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%. After FDA approval in 1995, many countries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1 gr b.i.d) for Helicobacter pylori treatment. In the beginning, eradication rates were above 90% in many countries; however, current studies have demonstrated a prominent decrease in successful treatment rates, even down to 60%. This unfavorable reduction stimulated searches for new treatment protocols. Treatment protocols differ according to country, prevalence, cost-effectiveness, antibiotic resistance, CYP2C19 polymorphism and eradication rates. Thus, each country/region needs to revise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori. This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations for rational therapeutic considerations for the eradication of the bacterium.